Effect of oral magnesium supplementation on insulin sensitivity and blood pressure in apparently healthy overweight adults: a randomised double-blinded controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN92199360

Enrollment

156

Registered

2007-12-18

Start date

2006-01-04

Completion date

Unknown

Last updated

2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight, obesity Nutritional, Metabolic, Endocrine Obesity

Interventions

12.3 mmol (300 mg) of elemental magnesium per day in the form of magnesium oxide or placebo. The total duration of treatment and the total duration of follow up are both 12 weeks (i.e., no follow-up).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 30 - 60 years 2. Body mass index greater than or equal to 23 kg/m^2 3. Have not taken any supplements or medications, including anti-diabetic drugs, anti-hypertensive drugs, steroids, or hormonal products, during the previous 4 weeks

Exclusion criteria

Exclusion criteria: 1. Pregnant women 2. Those suffering from chronic illnesses, including: 2.1. Chronic liver and renal diseases 2.2. Severe bradycardia 2.3. Myasthenia gravis 2.4. Hypermagnesemia

Design outcomes

Primary

Measure	Time frame
1. The HOMeostasis model Assessment of Insulin Resistance (HOMA-IR) 2. Quantitative Insulin Sensitivity Check Index (QUICKI) 3. Systolic BP 4. Diastolic BP Primary outcomes measured at baseline and 12 weeks (at the end of this study).	—

Secondary

Measure	Time frame
1. Lipids 2. Serum trace minerals (magnesium, calcium, and phosphorus) Secondary outcomes measured at baseline and 12 weeks (at the end of this study).	—

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026